The company also reported a 63 percent drop in cash on hand since the end of last year.
Earnings fell 11 cents a share for the quarter ended Sept. 30, compared with a loss of 9 cents, or $6.2 million, for the year-ago period. Analysts had expected a drop of 6 cents, according to Thomson Reuters.
Memory said revenue decreased 14 percent to $4.3 million. The company attributed most of the drop to last year's breakup of its partnership with biotech giant Amgen Inc.
Memory's cash in hand fell to $14 million from $38.2 million at the end of 2007. The company said it has sufficient cash to take it into the first half of 2009.
Memory's shares rose 2 cents, or 11 percent, to 20 cents Thursday in Nasdaq Capital Market trading.
In September, the company said it would cut more than half its workforce in an effort to reduce costs and direct its resources toward clinical development programs. Memory had about 55 employees at the time, according to financial Web sites.
Half the cuts were to be made immediately, with the rest coming over the next six months, the company said at the time.
Two weeks ago, following a drop in market value, the company said the listing of its common stock would be transferred to The Nasdaq Capital Market from The Nasdaq Global Market.
For the nine months ended Sept. 30, Memory said its losses widened to $34.8 million, or 46 cents a share, from $25.7 million, or 36 cents, for the same period in 2007.
To see more of The Record, or to subscribe to the newspaper, go to http://www.NorthJersey.com. Copyright (c) 2008, The Record, Hackensack, N.J. Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index